The rising costs of prescription medicine took center stage during a hearing held by the Ways and Means Committee in the U.S. House of Representatives.
Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.
Johnson & Johnson will start adding the price of the company’s medicines to television commercials by March 2019, becoming the first drugmaker to heed a call by U.S. President Donald Trump.
Novartis AG Chief Executive Vas Narasimhan said his company’s prescription drug prices have been “flat to negative” over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits.
U.S. drugmaker Pfizer Inc. said the company’s Chief Executive Albert Bourla plans to testify during February 2018 at a Senate hearing examining rising prescription drug prices.
Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.
U.S. President Donald Trump said Americans are paying more than people in other countries for prescription drugs, according to excerpts from the State of the Union address.
A powerful U.S. Senate committee invited seven pharmaceutical companies to testify at a hearing during February 2019 examining rising prescription drug prices.
U.S. Senator Bernie Sanders sent a letter to Catalyst Pharmaceuticals asking the company to justify the decision to charge $375,000 annually for a medication that for years has been available to patients for free.
A U.S. judge threw out the state of Maryland’s bid to protect the healthcare law known as Obamacare in a ruling that also sidestepped a decision on whether President Donald Trump’s appointment of Matthew Whitaker as acting attorney general was lawful.